Tx of Advanced HCC

CME

Education and Resources to Optimize Patient Care in Hepatocellular Carcinoma

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: February 01, 2023

Expiration: January 31, 2024

Activity

Progress
1
Course Completed

  1. Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808-820.
  2. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-873.
  3. Atezolizumab prescribing information South San Francisco, CA: Genentech; 2022.
  4. Bevacizumab prescribing information. South San Francisco, CA: Genentech; 2022.
  5. Finn RS, Quin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.
  6. Pickwell-Smith BA, So AC, Board RE. Managing side effects of cancer immunotherapy for the acute physician. Br J Hosp Med (Lond). 2018;79:372-377.
  7. Nivolumab prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2022.
  8. Pembrolizumab prescribing information. Rahway, NJ: Merck; 2022.
  9. Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960-974.
  10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
  11. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
  12. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173.
  13. Lenvatinib prescribing information. Nutley, NJ: Eisai; 2022
  14. Sorafenib prescribing information. Wayne, NJ: Bayer HealthCare; 2010.
  15. Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J Clin Oncol. 2021;39:2991-3001.
  16. Abou-Alfa GK, Lam Chan S, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022. Abstract 379.
  17. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8).
  18. Tremelimumab prescribing information. Wilmington, DE: AstraZeneca; 2022.
  19. Durvalumab prescribing information. Wilmington, DE: AstraZeneca; 2022.
  20. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502.
  21. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77-90.
  22. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54-63.
  23. Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995-1008.
  24. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960-2970.
  25. Llovet JM, Kudo M, Cheng A, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. Presented at: American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2019. Abstract TPS4152.
  26. Finn RS, Kudo M, Merle P, et al. Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Presented at: European Society for Medical Oncology Congress; September 9-13, 2022. Abstract LBA34.
  27. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66.
  28. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282-296.
  29. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193-202.
  30. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564.
  31. Cabozantinib prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2022.
  32. Ramucirumab prescribing information. Indianapolis, IN: Lilly; 2022.
  33. Melero I. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040. Presented at: European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract SO-12.
  34. Ipilimumab prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2022.
  35. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940-952.
  36. Finn, RS, Edeline, J, Bouattour, M, et al. Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study. Presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 4072.
  37. Qin, S, Chen, Z, Fang, W, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022. Abstract 383.
  38. Zheng J, Chou JF, Gönen M, et al. Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg. 2017;266:693-701.
  39. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344-1354.

  1. Lee MS, Ryoo BY, Hsu CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808-820.
  2. Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862-873.
  3. Atezolizumab prescribing information South San Francisco, CA: Genentech; 2022.
  4. Bevacizumab prescribing information. South San Francisco, CA: Genentech; 2022.
  5. Finn RS, Quin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894-1905.
  6. Pickwell-Smith BA, So AC, Board RE. Managing side effects of cancer immunotherapy for the acute physician. Br J Hosp Med (Lond). 2018;79:372-377.
  7. Nivolumab prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2022.
  8. Pembrolizumab prescribing information. Rahway, NJ: Merck; 2022.
  9. Bruix J, Chan SL, Galle PR, et al. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960-974.
  10. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
  11. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
  12. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-1173.
  13. Lenvatinib prescribing information. Nutley, NJ: Eisai; 2022
  14. Sorafenib prescribing information. Wayne, NJ: Bayer HealthCare; 2010.
  15. Kelley RK, Sangro B, Harris W, et al. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J Clin Oncol. 2021;39:2991-3001.
  16. Abou-Alfa GK, Lam Chan S, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022. Abstract 379.
  17. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1(8).
  18. Tremelimumab prescribing information. Wilmington, DE: AstraZeneca; 2022.
  19. Durvalumab prescribing information. Wilmington, DE: AstraZeneca; 2022.
  20. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;389:2492-2502.
  21. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77-90.
  22. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54-63.
  23. Kelley RK, Rimassa L, Cheng AL, et al. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23:995-1008.
  24. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol. 2020;38:2960-2970.
  25. Llovet JM, Kudo M, Cheng A, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study. Presented at: American Society of Clinical Oncology Annual Meeting; May 31 - June 4, 2019. Abstract TPS4152.
  26. Finn RS, Kudo M, Merle P, et al. Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Presented at: European Society for Medical Oncology Congress; September 9-13, 2022. Abstract LBA34.
  27. Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66.
  28. Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282-296.
  29. Finn RS, Ryoo BY, Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193-202.
  30. Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial. JAMA Oncol. 2020;6:e204564.
  31. Cabozantinib prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2022.
  32. Ramucirumab prescribing information. Indianapolis, IN: Lilly; 2022.
  33. Melero I. Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040. Presented at: European Society for Medical Oncology World Congress on Gastrointestinal Cancer; June 29 - July 2, 2022. Abstract SO-12.
  34. Ipilimumab prescribing information. Princeton, NJ: Bristol-Myers Squibb; 2022.
  35. Zhu AX, Finn RS, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018;19:940-952.
  36. Finn, RS, Edeline, J, Bouattour, M, et al. Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study. Presented at: American Society of Clinical Oncology Annual Meeting; June 4-8, 2021. Abstract 4072.
  37. Qin, S, Chen, Z, Fang, W, et al. Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): phase 3 KEYNOTE-394 study. Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposium; January 20-22, 2022. Abstract 383.
  38. Zheng J, Chou JF, Gönen M, et al. Prediction of hepatocellular carcinoma recurrence beyond Milan criteria after resection: validation of a clinical risk score in an international cohort. Ann Surg. 2017;266:693-701.
  39. Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16:1344-1354.